Marc Arbyn (Belgium)

Sciensano Cancer epidemiology

Coordinator of the Unit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano). Juliette Wytsmanstreet 14, B-1050 Brussels, BELGIUM M Arbyn has diplomas of MD, MSc, Dr in tropical medicine and PhD in medicine & health Science. After a career in Africa with Médecins Sans Frontières, he got involved in cancer research in Europe. MA coordinated the evaluation of new screening methods in the framework of the European Network of Cervical Cancer Screening and is editor- of the European Guidelines for Cervical Cancer Screening and associated Supplements on HPV screening. His main activity deals with systematic reviews, Cochrane reviews and meta-analyses regarding prevention and treatment of HPV-related cancers and their precursors (cervical cancer screening, diagnosis and treatment of cervical precancer, anal cancer and oropharyngeal cancer. MA is involved in several international networks dealing with biobank-based cancer research (addressing etiological questions and possible application of biomarkers in screening), clinical validation of tests applied in screening, diagnosis and prognosis prediction and offers epidemiological support to health authorities regarding implementation of cervical cancer prevention. MA is author of >250 papers, published in peer-reviewed journals, and a few dozens of book chapters or monographies related to cancer prevention. MA is also specialised in trend analysis and age-cohort-period modelling of cancer incidence and mortality. MA is principle investigator of the VALGENT (VALidation of hpv GENotyping Tests) and VALHUDES (VALidation of HUman papillomavirus assays and collection DEvices for HPV testing on Self-samples and urine samples) studies. These are independent researcher-induced protocols used for HPV test comparison and validation on clinician-collected cervical samples, vaginal self-samples and urine. MA is currently updating methods for test validation in collaboration with an international network of experts involving clinical epidemiologist and virologists. MA is coordinator of the Unit of Cancer Epidemiology, which is part of the Belgian Cancer Centre at the Scientific Institute of Public Health in Brussels. He was member of the Board of Directors of the International Papillomavirus Society (IPV) from 2012 to 2018 and congress president of EUROGIN 2018 (Lisbon, Portugal).

Presenter of 4 Presentations

Conference Calendar

HPV testing in low- and middle income countries Hall A

Introduction by Chairs (ID 1714)

Session Date

07/23/2020

Session Time

10:40 - 11:45

Room

Hall A

Session Type

Dedicated Symposium

Session Name

HPV testing in low- and middle income countries

Lecture Time

10:40 - 10:43

Presenter

Marc Arbyn (Belgium)

Authors

Marc Arbyn (Belgium)

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Public Health / Epidemiology / Global Impact of HPV and Cervical Cancer Prevention ePoster

WORLDWIDE BURDEN OF CERVICAL CANCER IN 2018 (ID 976)

Session Date

07/21/2020

Session Time

10:00 - 17:00

Room

ePoster

Session Type

Poster Viewing - 20-24 July

Session Name

Public Health / Epidemiology / Global Impact of HPV and Cervical Cancer Prevention

Lecture Time

10:00 - 10:01

Presenter

Marc Arbyn (Belgium)

Authors

Abstract

Abstract

Introduction

The knowledge that persistent human papillomavirus (HPV) infection is the main cause of cervical cancer has resulted in the development of prophylactic vaccines to prevent the HPV infection and HPV assays that detect the virus Given the recent call from WHO to scale up preventive, screening and treatment interventions to eliminate cervical cancer as a public health problem during this century, it is timely to assess the current burden of the disease as a baseline from which to assess the impact of the global initiative.

Methods

Visual and tabular descriptions of national estimates of cervical cancer incidence and mortality in 2018 are presented from GLOBOCAN, the recently compiled database from IARC of cancer estimates for 185 countries.

Results

There were an estimated 570,000 cases of cervical cancer and 311,000 deaths from the disease in 2018. It is the fourth most common female cancer ranking after breast cancer (2.1 million cases), colorectal cancer (0.8 million cases) and lung cancer (0.7 million). The incidence of cervical cancer varies widely among countries with estimated world-age-standardised rates ranging from less than 1 to 75 per 100,000. Cervical cancer is the leading cause of cancer-related death among women in Eastern, Western, Middle and Southern Africa. The highest incidence rate is estimated in the Kingdom of Eswatini, with ~ 6.5% of women developing cervical cancer before the age of 75. China and India contribute over one third of the global cervical burden with 106,000 and 97,000 cases and 48,000 and 60,000 deaths, respectively. More than the other major cancers, the disease affects women <45 years.

Conclusions

Cervical cancer continues to be a major public health problem affecting young women particularly in low and middle-income countries. The global scale-up of HPV vaccination and HPV-based screening – including self-sampling – may make cervical cancer a rare disease in the decades to come.

Hide

HPV testing in low- and middle income countries Hall A

Principles of validation of HPV assays usable in low-resource countries. (ID 1569)

Session Date

07/23/2020

Session Time

10:40 - 11:45

Room

Hall A

Session Type

Dedicated Symposium

Session Name

HPV testing in low- and middle income countries

Lecture Time

10:43 - 10:58

Presenter

Marc Arbyn (Belgium)

Authors

Marc Arbyn (Belgium)

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 6: SCREENING III. Implementation, dissemination, and communication Hall E

META-ANALYSIS ON THE ACCURACY OF METHODS TO TRIAGE HRHPV-POSITIVE WOMEN (ID 1252)

Session Date

07/22/2020

Session Time

11:35 - 13:15

Room

Hall E

Session Type

Public Health Oral Session

Session Name

Oral Session 6: SCREENING III. Implementation, dissemination, and communication

Lecture Time

12:47 - 12:59

Presenter

Marc Arbyn (Belgium)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Moderator of 3 Sessions

Conference Calendar

Dedicated Symposium

00890 - HPV testing in low- and middle income countries (ID 154)

Session Type

Dedicated Symposium

Session Date

07/23/2020

Session Time

10:40 - 11:45

Room

Hall A

Chair(s)

Watch Stream
Session Webcast

Session Webcast

[{"name":"Introduction by Chairs \u003Csmall\u003E(ID 1714)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1714,"presentation":"Introduction by Chairs \u003Csmall\u003E(ID 1714)\u003C\/small\u003E","session":"HPV testing in low- and middle income countries","presenter":"Marc Arbyn (Belgium)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/2141.jpg"},"playlist":[{"name":"ntroduction by Chairs","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/154\/Marc Arbyn IPVC20 1714 Introduction by Chairs.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/154\/Marc Arbyn IPVC20 1714 Introduction by Chairs.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/154\/4E81BEAD.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/154\/Marc Arbyn IPVC20 1714 Introduction by Chairs.vtt"}]},{"name":"Principles of validation of HPV assays usable in low-resource countries. \u003Csmall\u003E(ID 1569)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1569,"presentation":"Principles of validation of HPV assays usable in low-resource countries. \u003Csmall\u003E(ID 1569)\u003C\/small\u003E","session":"HPV testing in low- and middle income countries","presenter":"Marc Arbyn (Belgium)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/2141.jpg"},"playlist":[{"name":"Principles of validation of HPV assays usable in low-resource countries.","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/154\/Marc Arbyn IPVC2020 P_1569.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/154\/Marc Arbyn IPVC2020 P_1569.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/154\/BF68D0D.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/154\/Marc Arbyn IPVC2020 P_1569.vtt"}]},{"name":"Validation of the Xpert HPV assay (Cepheid) and the careHPV assay (Qiagen) \u003Csmall\u003E(ID 1570)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1570,"presentation":"Validation of the Xpert HPV assay (Cepheid) and the careHPV assay (Qiagen) \u003Csmall\u003E(ID 1570)\u003C\/small\u003E","session":"HPV testing in low- and middle income countries","presenter":"Kate Cuschieri (United Kingdom)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/73.jpg"},"playlist":[{"name":"Validation of the Xpert HPV assay (Cepheid) and the careHPV assay (Qiagen)","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/154\/Kate Cuschieri IPVC20 1570.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/154\/Kate Cuschieri IPVC20 1570.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/154\/7355C419.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/154\/Kate Cuschieri IPVC20 1570.vtt"}]},{"name":"Validation of Chinese new HPV assays \u003Csmall\u003E(ID 1571)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1571,"presentation":"Validation of Chinese new HPV assays \u003Csmall\u003E(ID 1571)\u003C\/small\u003E","session":"HPV testing in low- and middle income countries","presenter":"Youlin Qiao (China)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/446.jpg"},"playlist":[{"name":"Youlin Qiao - IPVC20 - Presentation 1,571","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/154\/Youlin Qiao - IPVC20 - P 1571.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/154\/Youlin Qiao - IPVC20 - P 1571.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/154\/B3A2A0BA.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/154\/Youlin Qiao - IPVC20 - P 1571.vtt"}]},{"name":"Validation of assays used for screening or triage in the Estampa study \u003Csmall\u003E(ID 1572)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1572,"presentation":"Validation of assays used for screening or triage in the Estampa study \u003Csmall\u003E(ID 1572)\u003C\/small\u003E","session":"HPV testing in low- and middle income countries","presenter":"Maribel Almonte (France)","photo":""},"playlist":[{"name":"Validation of assays used for screening or triage in the Estampa study","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/154\/GMT20200710-155733_Maribel-Al_1920x1020-0.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/154\/GMT20200710-155733_Maribel-Al_1920x1020-0.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/154\/DA4D5473.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/154\/GMT20200710-155733_Maribel-Al_1920x1020-0.vtt"}]}]

Public Health Oral Session

00920 - Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening (ID 40)

Session Type

Public Health Oral Session

Session Date

07/23/2020

Session Time

12:20 - 14:20

Room

Hall E

Chair(s)

Watch Stream
Session Webcast

Session Webcast

[{"name":"TRIAGING HPV POSITIVE WOMEN WITH LOW-GRADE CYTOLOGY: EVIDENCE FROM 10 YEAR FOLLOW-UP OF THE ARTISTIC TRIAL COHORT \u003Csmall\u003E(ID 1069)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1069,"presentation":"TRIAGING HPV POSITIVE WOMEN WITH LOW-GRADE CYTOLOGY: EVIDENCE FROM 10 YEAR FOLLOW-UP OF THE ARTISTIC TRIAL COHORT \u003Csmall\u003E(ID 1069)\u003C\/small\u003E","session":"Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening\u00a0","presenter":"Clare Gilham (United Kingdom)","photo":""},"playlist":[{"name":"TRIAGING HPV POSITIVE WOMEN WITH LOW-GRADE CYTOLOGY EVIDENCE FROM 10 YEAR FOLLOW-UP OF THE ARTISTIC ","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Clare Gilham IPVC20 1069 TRIAGING HPV POSITIVE WOMEN WITH LOW-GRADE CYTOLOGY EVIDENCE FROM 10 YEAR FOLLOW-UP OF THE ARTISTIC TRIAL COHORT.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/40\/Clare Gilham IPVC20 1069 TRIAGING HPV POSITIVE WOMEN WITH LOW-GRADE CYTOLOGY EVIDENCE FROM 10 YEAR FOLLOW-UP OF THE ARTISTIC TRIAL COHORT.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/E99BB056.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Clare Gilham IPVC20 1069 TRIAGING HPV POSITIVE WOMEN WITH LOW-GRADE CYTOLOGY EVIDENCE FROM 10 YEAR FOLLOW-UP OF THE ARTISTIC TRIAL COHORT.vtt"}]},{"name":"EVALUATING COMBINED SCREENING AND TRIAGE STRATEGIES IN 4,600 WOMEN FROM THE IMPROVING RISK INFORMED HPV SCREENING (IRIS) STUDY \u003Csmall\u003E(ID 1350)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1350,"presentation":"EVALUATING COMBINED SCREENING AND TRIAGE STRATEGIES IN 4,600 WOMEN FROM THE IMPROVING RISK INFORMED HPV SCREENING (IRIS) STUDY \u003Csmall\u003E(ID 1350)\u003C\/small\u003E","session":"Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening\u00a0","presenter":"Nicolas Wentzensen (United States of America)","photo":""},"playlist":[{"name":"Nicolas Wentzensen - EVALUATING COMBINED SCREENING AND TRIAGE STRATEGIES IN 4,600 WOMEN FROM THE IMP","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Nicolas Wentzensen - EVALUATING COMBINED SCREENING AND TRIAGE STRATEGIES IN 4,600 WOMEN FROM THE IMPROVING RISK INFORMED HPV SCREENING (IRIS) STUDY.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/40\/Nicolas Wentzensen - EVALUATING COMBINED SCREENING AND TRIAGE STRATEGIES IN 4,600 WOMEN FROM THE IMPROVING RISK INFORMED HPV SCREENING (IRIS) STUDY.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/26C69DD6.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Nicolas Wentzensen - EVALUATING COMBINED SCREENING AND TRIAGE STRATEGIES IN 4,600 WOMEN FROM THE IMPROVING RISK INFORMED HPV SCREENING (IRIS) STUDY.vtt"}]},{"name":"TRENDS IN CERVICAL CANCER SCREENING EVERY 3 OR 5 YEARS AS PER NEW GUIDELINES IN DAVIDSON COUNTY, TENNESSEE, UNITED STATES WOMEN DURING 2006-2017 \u003Csmall\u003E(ID 863)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":863,"presentation":"TRENDS IN CERVICAL CANCER SCREENING EVERY 3 OR 5 YEARS AS PER NEW GUIDELINES IN DAVIDSON COUNTY, TENNESSEE, UNITED STATES WOMEN DURING 2006-2017 \u003Csmall\u003E(ID 863)\u003C\/small\u003E","session":"Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening\u00a0","presenter":"Manideepthi Pemmaraju (United States of America)","photo":""},"playlist":[{"name":"TRENDS IN CERVICAL CANCER SCREENING EVERY 3 OR 5 YEARS AS PER NEW GUIDELINES IN DAVIDSON COUNTY, TEN","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Manideepthi Pemmaraju - IPVC20 - 863.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/40\/Manideepthi Pemmaraju - IPVC20 - 863.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/22F65966.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Manideepthi Pemmaraju - IPVC20 - 863.vtt"}]},{"name":"EVOLVEMENT OF CERVICAL CANCER SCREENING PROGRAMS IN LATIN AMERICA \u003Csmall\u003E(ID 855)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":855,"presentation":"EVOLVEMENT OF CERVICAL CANCER SCREENING PROGRAMS IN LATIN AMERICA \u003Csmall\u003E(ID 855)\u003C\/small\u003E","session":"Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening\u00a0","presenter":"Raul H. Murillo (Colombia)","photo":""},"playlist":[{"name":"EVOLVEMENT OF CERVICAL CANCER SCREENING PROGRAMS IN LATIN AMERICA","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/855.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/40\/855.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/DD372A01.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/855.vtt"}]},{"name":"HPV18 WHOLE-GENOME SEQUENCE DATA REVEALS IMPORTANT ASSOCIATIONS OF SUBLINEAGES WITH HISTOLOGY-SPECIFIC CANCER RISK \u003Csmall\u003E(ID 1043)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1043,"presentation":"HPV18 WHOLE-GENOME SEQUENCE DATA REVEALS IMPORTANT ASSOCIATIONS OF SUBLINEAGES WITH HISTOLOGY-SPECIFIC CANCER RISK \u003Csmall\u003E(ID 1043)\u003C\/small\u003E","session":"Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening\u00a0","presenter":"Yanzi Xiao (United States of America)","photo":""},"playlist":[{"name":"HPV18 WHOLE-GENOME SEQUENCE DATA REVEALS IMPORTANT ASSOCIATIONS OF SUBLINEAGES WITH HISTOLOGY-SPECIF","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Yanzi Xiao - IPVC20 - 1043.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/40\/Yanzi Xiao - IPVC20 - 1043.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/E9EEB14D.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Yanzi Xiao - IPVC20 - 1043.vtt"}]},{"name":"CIN2+ CASES MISSED BY LBC OR HPV TESTING AT 48-MONTH EXIT: HPV FOCAL CERVICAL CANCER SCREENING TRIAL \u003Csmall\u003E(ID 969)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":969,"presentation":"CIN2+ CASES MISSED BY LBC OR HPV TESTING AT 48-MONTH EXIT: HPV FOCAL CERVICAL CANCER SCREENING TRIAL \u003Csmall\u003E(ID 969)\u003C\/small\u003E","session":"Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening\u00a0","presenter":"Lovedeep Gondara (Canada)","photo":""},"playlist":[{"name":"CIN2+ CASES MISSED BY LBC OR HPV TESTING AT 48-MONTH EXIT: HPV FOCAL CERVICAL CANCER SCREENING TRIAL","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Lovedeep Gondara - IPVC20 - 969 - CIN2 CASES MISSED BY LBC OR HPV TESTING AT 48-MONTH EXIT HPV FOCAL CERVICAL CANCER SCREENING TRIAL.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/40\/Lovedeep Gondara - IPVC20 - 969 - CIN2 CASES MISSED BY LBC OR HPV TESTING AT 48-MONTH EXIT HPV FOCAL CERVICAL CANCER SCREENING TRIAL.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/BDC5B9B7.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Lovedeep Gondara - IPVC20 - 969 - CIN2 CASES MISSED BY LBC OR HPV TESTING AT 48-MONTH EXIT HPV FOCAL CERVICAL CANCER SCREENING TRIAL.vtt"}]},{"name":"PAST SCREENING HISTORY SHOULD BE CONSIDERED IN RISK BASED CERVICAL SCREENING \u003Csmall\u003E(ID 869)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":869,"presentation":"PAST SCREENING HISTORY SHOULD BE CONSIDERED IN RISK BASED CERVICAL SCREENING \u003Csmall\u003E(ID 869)\u003C\/small\u003E","session":"Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening\u00a0","presenter":"Didem Egemen (United States of America)","photo":""},"playlist":[{"name":"PAST SCREENING HISTORY SHOULD BE CONSIDERED IN RISK BASED CERVICAL SCREENING","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Didem Egemen- IPVC20 - PRESENTATION id 869.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/40\/Didem Egemen- IPVC20 - PRESENTATION id 869.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/A57789A2.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Didem Egemen- IPVC20 - PRESENTATION id 869.vtt"}]},{"name":"IMPACT OF SCALING UP HPV SCREENING IN MALAYSIA \u003Csmall\u003E(ID 724)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":724,"presentation":"IMPACT OF SCALING UP HPV SCREENING IN MALAYSIA \u003Csmall\u003E(ID 724)\u003C\/small\u003E","session":"Oral Session 13: SCREENING V. Evaluation and Impact of cervical cancer screening\u00a0","presenter":"Adam Keane (Australia)","photo":""},"playlist":[{"name":"IMPACT OF SCALING UP HPV SCREENING IN MALAYSIA","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Adam Keane - IPVC20 - PRESENTATION id 724.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/40\/Adam Keane - IPVC20 - PRESENTATION id 724.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/C6B3599F.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/40\/Adam Keane - IPVC20 - PRESENTATION id 724.vtt"}]}]

Plenary Session

01000 - IPVC Plenary Session 4 (ID 52)

Session Type

Plenary Session

Session Date

07/24/2020

Session Time

10:30 - 12:05

Room

Hall A

Chair(s)

Watch Stream
Session Webcast

Session Webcast

[{"name":"Introduction by Chairs \u003Csmall\u003E(ID 1718)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1718,"presentation":"Introduction by Chairs \u003Csmall\u003E(ID 1718)\u003C\/small\u003E","session":"IPVC Plenary Session 4","presenter":"John Doorbar (United Kingdom)","photo":""},"playlist":[{"name":"Introduction by Chairs","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/52\/John Doorbar IPVC20 1718 Introduction by Chairs.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/52\/John Doorbar IPVC20 1718 Introduction by Chairs.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/52\/1E77E6CD.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/52\/John Doorbar IPVC20 1718 Introduction by Chairs.vtt"}]},{"name":"Resource-appropriate immunotherapeutic approaches to the elimination of cervical cancer \u003Csmall\u003E(ID 108)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":108,"presentation":"Resource-appropriate immunotherapeutic approaches to the elimination of cervical cancer \u003Csmall\u003E(ID 108)\u003C\/small\u003E","session":"IPVC Plenary Session 4","presenter":"Corey Casper (United States of America)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/70.jpg"},"playlist":[{"name":"Resource-appropriate immunotherapeutic approaches to the elimination of cervical cancer","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/52\/Corey Casper, MD MPH - IPVC20 - 108 - Presentation Name Resource-appropriate immunotherapeutic approaches to the elimination of cervical cancer.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/52\/Corey Casper, MD MPH - IPVC20 - 108 - Presentation Name Resource-appropriate immunotherapeutic approaches to the elimination of cervical cancer.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/52\/5CE2E304.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/52\/Corey Casper, MD MPH - IPVC20 - 108 - Presentation Name Resource-appropriate immunotherapeutic approaches to the elimination of cervical cancer.vtt"}]},{"name":"Use of Deep Learning into Cervical Cancer Screening \u003Csmall\u003E(ID 109)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":109,"presentation":"Use of Deep Learning into Cervical Cancer Screening \u003Csmall\u003E(ID 109)\u003C\/small\u003E","session":"IPVC Plenary Session 4","presenter":"Mark Schiffman (United States of America)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/46.jpg"},"playlist":[{"name":"Use of Deep Learning into Cervical Cancer Screening","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/52\/IPVC 20 - Mark Schiffman - P109 - S1000.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/52\/IPVC 20 - Mark Schiffman - P109 - S1000.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/52\/A153D5DD.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/52\/IPVC 20 - Mark Schiffman - P109 - S1000.vtt"}]},{"name":"Oral Cancer Therapeutics \u003Csmall\u003E(ID 110)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":110,"presentation":"Oral Cancer Therapeutics \u003Csmall\u003E(ID 110)\u003C\/small\u003E","session":"IPVC Plenary Session 4","presenter":"Robert L. Ferris (United States of America)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/112.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/52\/PRESENTATION id 110.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/52\/PRESENTATION id 110.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/52\/A823A273.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/52\/PRESENTATION id 110.vtt"}]}]